FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia

The FDA has approved ropeginterferon alfa-2b (Besremi) for treating adult patients with essential thrombocythemia (ET), marking the first new drug approval for ET in the US since 1997. This decision, based on phase 3 SURPASS-ET and phase 2b EXCEED-ET trials, demonstrates ropeginterferon alfa-2b's superior efficacy over anagrelide for patients resistant or intolerant to hydroxyurea.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.